India markets closed
  • BSE SENSEX

    40,522.10
    +376.60 (+0.94%)
     
  • Nifty 50

    11,889.40
    +121.65 (+1.03%)
     
  • Dow

    27,685.38
    -650.19 (-2.29%)
     
  • Nasdaq

    11,358.94
    -189.34 (-1.64%)
     
  • BTC-INR

    986,743.19
    +17,309.19 (+1.79%)
     
  • CMC Crypto 200

    266.57
    +3.16 (+1.20%)
     
  • Hang Seng

    24,787.19
    -131.59 (-0.53%)
     
  • Nikkei

    23,485.80
    -8.54 (-0.04%)
     
  • EUR/INR

    87.1372
    -0.1859 (-0.21%)
     
  • GBP/INR

    96.0112
    -0.2109 (-0.22%)
     
  • AED/INR

    20.0320
    -0.0480 (-0.24%)
     
  • INR/JPY

    1.4182
    +0.0026 (+0.18%)
     
  • SGD/INR

    54.2100
    -0.1010 (-0.19%)
     

AstraZeneca resumes trial of COVID antibody

AstraZeneca trails have resumed for the COVID vaccine. ET Now's Pankaj reports, last Tuesday AstraZeneca said that due to an illness as far as one patient is concerned they are stopping the trial that's the protocol they need to follow and take a pause on their clinical trial. Oxford and AstraZeneca are doing the trail together and they announced that trial would be continued according to the research that they have indicated.

However, due to security reasons, personal reasons they have not given details of what happened to the one patient because of which the trail was paused. It also indicated the issue was particularly to the patient and not because of the vaccine.